Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice
about
Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemiaDisrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal modelsDrug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseaseiTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and diseaseAmitriptyline-mediated cognitive enhancement in aged 3×Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activityEnvironmental enrichment and brain repair: harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience-dependent plasticityAPP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease.Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession.A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's diseasePharmacomimetics of exercise: novel approaches for hippocampally-targeted neuroprotective agents.Adverse stress, hippocampal networks, and Alzheimer's disease.Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD miceAntidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.The plasma membrane redox system is impaired by amyloid β-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice.Depressive Symptoms in Clinical and Incipient Alzheimer's Disease.Gonadotropin-releasing hormone receptor system: modulatory role in aging and neurodegeneration.Complex and multidimensional lipid raft alterations in a murine model of Alzheimer's diseaseUsing mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse modelsDefects in tongue papillae and taste sensation indicate a problem with neurotrophic support in various neurological diseases.Impaired adaptive cellular responses to oxidative stress and the pathogenesis of Alzheimer's diseaseCombination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease.An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice.Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept).Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice.Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease.Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humansSleep disturbances in Alzheimer's and Parkinson's diseases.Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's diseaseImmunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 BalanceThe association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.Serotonin 6 receptor controls Alzheimer's disease and depressionAcute kidney injury leads to inflammation and functional changes in the brain.Activity-dependent, stress-responsive BDNF signaling and the quest for optimal brain health and resilience throughout the lifespanCerebral amyloid deposition and serotoninergic innervation in Parkinson disease.Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's diseaseRedundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo.Escitalopram attenuates β-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt/GSK-3β pathwayLong-term trihexyphenidyl exposure alters neuroimmune response and inflammation in aging rat: relevance to age and Alzheimer's disease
P2860
Q24650258-C67394DB-E454-47D2-A965-27BE87642D0FQ26995918-D2CA54DA-0191-44A1-A353-00B59DCD3E4DQ27024122-B958CDE2-5EE0-4D20-863E-6268764E9D8BQ27300851-8D464071-2376-4DF6-93EE-4E21DD1A4190Q27334070-7D6A69BC-1094-4810-ADBC-4E4F58630923Q28304384-DA98C332-45C3-4DC5-B521-EF082A9470C7Q30455082-AF209C39-FD9F-4304-9BB4-4E4B090FC758Q30497430-260D6E41-BEF4-482B-BC53-6342EC5871DAQ30537554-DAEB2E87-846D-4109-BB4C-5E6039D5060BQ30538459-C5148C0B-5FA7-4840-B85D-9636E08E40A5Q33652095-5D36500E-EE0B-4703-8934-CE8C21E2C27EQ33708011-65E29CFA-D6DD-4BB3-9E16-B3DA0641EA71Q33729293-F375DBA5-6CF7-46DD-9410-CBAA483FF2A1Q33751924-90B09E17-0A54-43F7-BB96-76E0F04333C3Q34079552-C250DD40-17C7-435D-97FB-E660455988BFQ34159225-33C66A8A-F37C-4593-A802-7BB30BFA6CB1Q34163446-E7855797-2CE0-47E9-8BA4-CB153BB03623Q34258591-9C9BD3BD-3185-4561-B3B8-4DCFE8C24F96Q34381556-DA2310C1-775C-40A1-90FF-A4F50DB03BADQ34418781-D1DEDE78-AAD5-4B48-9A9F-7174AC5A2B07Q34588289-44AE90CD-5CCA-4670-BB70-3EE87869682AQ34700226-24A87DB0-2043-4109-9FF1-93890CE69603Q34714277-07758CC2-D4E5-4E31-9F73-AAAFF7CB7DFFQ34723920-949607D0-7ECE-4A1E-8EC3-1E6E39F4552BQ34732823-7C74C808-DA99-4D5C-B5C6-A0EE5AF27F0CQ35053378-F7BD93C1-088A-44C3-90BB-E5AD8CBF28AAQ35179010-1516E93C-4084-4A06-874F-1BC8B304EB1FQ35202803-420A216C-5994-4848-8772-DD16197192ACQ35981780-126BDD30-0144-4F4D-B1D1-ABD8AC67E307Q36010517-53A41F41-1CB2-4FCD-BA75-DCC8D91903A9Q36067334-E0D6517B-77A8-4EEC-8D1D-DF45E2646123Q36252668-4E5E8EAD-78E9-48F8-AF0B-0B2D1E0BA48EQ36413592-6FCEC318-7717-498E-852C-60083DDE8EB3Q36736770-E55567A1-7CF4-4543-A47C-8AA9B8B7BD1BQ36775197-C8F1C7A3-CF30-49C5-AF0D-59958F2A56F1Q36899059-1EB56BBF-5EEF-4012-9940-51392EE4AD3AQ36997908-335DD8C1-7869-4155-BBAC-CB149C1CDBC3Q37018138-FE8ABFC4-19FE-42C8-B67F-53036AE9745AQ37046351-85F0FAC2-0BF0-40CE-AF60-812D60CAA4E4Q37089887-451F89E4-BB25-4B80-A159-768A9B815951
P2860
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prophylactic treatment with pa ...... tau pathologies in 3xTgAD mice
@ast
Prophylactic treatment with pa ...... tau pathologies in 3xTgAD mice
@en
type
label
Prophylactic treatment with pa ...... tau pathologies in 3xTgAD mice
@ast
Prophylactic treatment with pa ...... tau pathologies in 3xTgAD mice
@en
prefLabel
Prophylactic treatment with pa ...... tau pathologies in 3xTgAD mice
@ast
Prophylactic treatment with pa ...... tau pathologies in 3xTgAD mice
@en
P2093
P2860
P1476
Prophylactic treatment with pa ...... tau pathologies in 3xTgAD mice
@en
P2093
Audrey J Gray
Bronwen Martin
Martin Brown
Michelle Pearson
Rhonda L Nelson
Robert F Clark
Stuart Maudsley
Titilola Iyun
Veerendra Madala Halagappa
Yasuji Matsuoka
P2860
P304
P356
10.1016/J.EXPNEUROL.2007.01.037
P407
P50
P577
2007-02-13T00:00:00Z